CXCR2+ Granulocytic Myeloid-Derived Suppressor Cells with the Development of CCA: A Possible Target for Intervention

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Preclinical data implicate the ELR+ chemokine/CXCR2 axes in the pathogenesis of CCA, warranting further studies to define its role in CCA.

The prognosis of CCA remains poor, which may be partly attributable to high rates of unresectability, recurrence, and suboptimal response to standard chemotherapy, highlighting the need for novel systemic therapies. However, to further these efforts, effective preclinical models for identifying and testing new targeted or immune-based therapies are needed. At the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium, a spontaneous murine model of CCA was used to better understand the biology underlying the pathogenesis of CCA.

By histology and immunohistochemistry (IHC) staining with digital quantification performed on archival human CCA, significantly higher levels of CD15+CXCR2+ granulocytic myeloid-derived suppressor cells (G-MDSC) were found compared with adjacent normal liver (P = .0019). In addition, the CXCR2 ligand, CXCL5, was significantly elevated in CCA tumors compared with adjacent normal liver (P =.0065). These data implicate the ELR+ chemokine/CXCR2 axes in the pathogenesis of CCA to mobilize and recruit immunosuppressive G-MDSC to the tumor microenvironment.

To better understand the biology of CCA tumors, histologic and gene-expression studies were conducted in hepatic tumors grown in the spontaneous murine CCA model, which is characterized by hepatic KRAS activation and loss of p53, and normal livers from littermate controls. In addition, flow cytometric analysis was performed on bone marrow, spleen, peripheral blood from hepatic tumors, as well as controls.

In spontaneous CCA mice, quantitative real-time polymerase chain reaction tests showed a significant increase in expression of granulocyte colony-stimulating factor (CSF), CSF1, CXCL1, CXCL2, and CXCL5 (P = .0001) in the hepatic tumors compared with normal livers. Consistent with observations in the primary human CCA, flow cytometric analysis of hepatic tumors showed significantly elevated levels of CD45-positive leukocytes comprised of immunosuppressive G-MDSC compared with normal littermate controls (P = .0007). Also, a higher proportion of granulocytes in the bone marrow and blood were observed in spontaneous CCA mice compared with normal littermate controls.

These data suggest that the ELR+ chemokine/CXCR2 axes may potentially be involved in CCA pathogenesis and supports the utility of the spontaneous murine CCA model in preclinical evaluations of potential therapeutic interventions targeting this pathway.

Source: Ullman NA, et al. J Clin Oncol. 2020;38(4_suppl). Abstract 565.

 

Related Items

First-Line Treatment of Advanced Biliary Tract Cancers (BTCs)
Ask the Expert
Use of first-line (1L) IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin (gem-cis) chemotherapy in patients with locally advanced or metastatic biliary tract cancers
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review: Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review: Cholangiocarcinoma
This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review: Cholangiocarcinoma
Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review: Cholangiocarcinoma
Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review: Cholangiocarcinoma
In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review: Cholangiocarcinoma
Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review: Cholangiocarcinoma
In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review: Cholangiocarcinoma
Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer.
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review: Cholangiocarcinoma
In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: